Solid Biosciences Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-174.3M | $-124.7M | $-96.0M | $-86.0M | $-72.2M | $-88.3M | $-117.2M | $-74.8M |
| Depreciation & Amortization | $1.6M | $2.5M | $2.6M | $2.4M | $3.0M | $3.9M | $2.8M | — |
| Depreciation | — | — | $2.6M | $2.4M | $3.0M | $3.9M | $2.8M | $1.6M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $16.9M | $10.5M | $7.6M | $7.5M | $13.4M | $11.6M | $14.2M | $6.0M |
| Net Cash from Operating Activities | $-156.3M | $-100.0M | $-94.2M | $-98.0M | $-77.8M | $-56.6M | $-92.7M | $-70.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.2M | $654.0K | $1.5M | $3.0M | $1.3M | $899.0K | $4.4M | $7.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-58.5M | $-16.1M | $9.7M | $59.2M | $-91.1M | $6.6M | $24.5M | $-26.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $194.4M | $122.4M | $3.1M | $74.8M | $135.0M | $128.7M | $57.9M | $131.5M |
| Net Change in Cash | $-20.3M | $6.3M | $-81.4M | $36.0M | $-33.9M | $78.7M | $-10.3M | $34.5M |
| Free Cash Flow | $-157.4M | $-100.7M | $-95.7M | $-101.0M | $-79.0M | $-57.5M | $-97.1M | $-78.0M |